RxDoctor Payments Data

Merajur Rahman, MD

Gastroenterology · New Hyde Park, NYNPI 1891010732

Payments from drug & device makers

$1,995in general payments, 2019–2025

Across 99 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$780
  • Intra-sana Laboratories$337
  • Redhill Biopharma Inc.$228
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$126
  • Gilead$110
  • QOL Medical, LLC$91
  • plus $322 from 11 others

What the payments were for

  • Consulting fees$251%
  • Food & beverage$1,67084%
  • Gifts$30015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,995 in reported general payments places this provider in the 45th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$24,764
Medicare patients
75
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide121$81,603
IbsrelaTenapanor Hcl30$53,455
XifaxanRifaximin14$30,405
CreonLipase/Protease/Amylase12$20,185
TrulancePlecanatide11$5,758
Entecavir11$3,747
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C17$2,292
Pantoprazole Sodium317$2,007
Sucralfate68$1,990
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$881
Famotidine61$424
Dicyclomine Hcl69$394
Baclofen45$344
Omeprazole40$316
Amitriptyline Hcl26$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$780$101,788133 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$126$38,45642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →